Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

PCRX stock hub

Pacira BioSciences, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

PCRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

910.9M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

PCRX

In the news

Latest news · PCRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E7.6

P25 12.3P50 18.4P75 33.1

Trailing P/E194.3

P25 14.9P50 23.2P75 38.5

ROE0.7

P25 -105.6P50 -46.5P75 -3.1

ROIC1.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All PCRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

255

Groups with data

Currency

USD

Showing 255 of 255 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001396814
Company name	Pacira BioSciences, Inc.
Country	United States
Country code	US
Cusip	695127100
Employees	829
Employees Change	39%
Employees Change Percent	4.94
Enterprise value	$1.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2011-02-03
Isin	US6951271005
Last refreshed	2026-05-10
Market cap	$910.9M
Market cap category	Small-Cap
Price	$23.15
Price currency	USD
Rev Per Employee	886,446.32x
Sector	Healthcare
Sic	2834
Symbol	PCRX
Website	https://www.pacira.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	0.56%
EV Earnings	217.96x
EV/EBIT	37.2x
EV/EBITDA	9.23x
EV/FCF	8.44x
EV/Sales	1.52x
FCF yield	14.57%
Forward P/E	7.61x
P/B ratio	1.39x
P/E ratio	194.25x
P/S ratio	1.24x
PE Ratio5 Y	84.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	4.1%
EBITDA Margin	16.5%
FCF margin	18.06%
Gross margin	79.34%
Gross Profit	$583M
Gross Profit Growth	6.88%
Gross Profit Growth Q	4.71%
Gross Profit Growth3 Y	8.46%
Gross Profit Growth5 Y	12.46%
Net Income	$5.1M
Net Income Growth Q	-39.4%
Net Income Growth Years	1%
Net Income Growth5 Y	-48.92%
Pretax Margin	1.79%
Profit Margin	0.7%
Profit Per Employee	$6,198
Profitable Years	1
ROA	1.35
Roa5y	2.89
ROCE	2.74
ROE	0.71
Roe5y	0.46
ROIC	1.35
Roic5y	5.75

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-6.91%
Cagr15y	5.18%
Cagr1y	-8.07%
Cagr3y	-18.58%
Cagr5y	-18.21%
EPS Growth Q	-30
EPS Growth Years	1
EPS Growth5 Y	-48.61
FCF Growth	-16.75%
FCF Growth Q	-14.7%
FCF Growth3 Y	8.24%
FCF Growth5 Y	27.91%
OCF Growth	-19.08%
OCF Growth Q	-27.58%
OCF Growth10 Y	18.63%
OCF Growth3 Y	2.1%
OCF Growth5 Y	11.4%
Revenue Growth	4.57x
Revenue Growth Q	5x
Revenue Growth Quarters	10x
Revenue Growth Years	15x
Revenue Growth3 Y	3.17x
Revenue Growth5 Y	10.65x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.53
Assets	$1.2B
Cash	$202.2M
Current Assets	$515M
Current Liabilities	$108.8M
Debt	$411.2M
Debt EBITDA	$3.02
Debt Equity	$0.63
Debt FCF	$3.1
Equity	$653.9M
Interest Coverage	1.82
Liabilities	$554.6M
Long Term Assets	$693.6M
Long Term Liabilities	$445.9M
Net Cash	$-209M
Net Cash By Market Cap	$-22.94
Net Debt EBITDA	$1.72
Net Debt Equity	$0.32
Net Debt FCF	$1.57
Tangible Book Value	$280.9M
Tangible Book Value Per Share	$7.15
WACC	4.64

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.73
Inventory Turnover	1.07
Net Working Capital	$213.8M
Quick ratio	3.01
Working Capital	$406.2M
Working Capital Turnover	$1.73

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	5.52%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-51.12%
1Y total return	-8.06%
200-day SMA	23.68
3Y total return	-46.02%
50-day SMA	23.43
50-day SMA vs 200-day SMA	50under200
5Y total return	-63.4%
All Time High	122
All Time High Change	-81.02%
All Time High Date	2015-02-25
All Time Low	6.16
All Time Low Change	275.81%
All Time Low Date	2011-02-16
ATR	1.15
Beta	0.32
Beta1y	0.67
Beta2y	0.84
Ch YTD	-10.55
High	24.42
High52	27.64
High52 Date	2025-09-03
High52ch	-16.24%
Low	23.08
Low52	18.8
Low52 Date	2026-01-20
Low52ch	23.14%
Ma50ch	-1.18%
Premarket Change Percent	2.54
Premarket Price	$24.24
Premarket Volume	21,366
Price vs 200-day SMA	-2.23%
RSI	41.95
RSI Monthly	46.21
RSI Weekly	49.39
Sharpe ratio	-0.14x
Sortino ratio	-0.05
Total Return	5.52%
Tr YTD	-10.55
Tr15y	113.17%
Tr1m	2.75%
Tr1w	-5.28%
Tr3m	10.24%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	2
Analyst Price Target Top	$35
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.52
Earnings EPS Estimate Growth	-16.13
Earnings Revenue Estimate	173,945,864x
Earnings Revenue Estimate Growth	2.97x
Operating Income	$30.1M
Operating Income Growth	-66.66
Operating Income Growth Q	-40.9
Operating Income Growth3 Y	-19.74
Operating Income Growth5 Y	-12.72
Operating margin	4.1
Price target	$29.4
Price Target Change	$27
Price Target Change Top	$51.19

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	36,391,069%
Float Percent	92.49%
Net Borrowing	-218,986,000
Shares Insiders	2.3%
Shares Institutions	119.01%
Shares Out	39,347,924
Shares Qo Q	-4.82%
Shares Yo Y	-5.52%
Short Float	20.31%
Short Ratio	11.24
Short Shares	18.78

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$76.2M
Average Volume	596,915.9x
Bv Per Share	16.63
CAPEX	$-9.5M
Ch10y	-51.12
Ch15y	113.2
Ch1m	2.75
Ch1w	-5.28
Ch1y	-8.06
Ch3m	10.24
Ch3y	-46.02
Ch5y	-63.4
Ch6m	4.99
Change	-2.07%
Change From Open	-3.1
Close	23.64
Days Gap	1.06
Depreciation Amortization	91,186,000
Dollar Volume	11,898,174
Earnings Date	2026-04-30
Earnings Time	amc
EBIT	$30.1M
EBITDA	$121.3M
EPS	$0.12
F Score	8
FCF	$132.7M
FCF EV Yield	11.85x
FCF Per Share	$3.37
Financing CF	-426,031,000
Fiscal Year End	December
Founded	2,006
Goodwill	19,773,000
Graham Number	6.67866
Graham Upside	-71.15
Income Tax	$8M
Investing CF	144,551,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Lynch Fair Value	$0.6
Lynch Upside	-97.43
Ma150	23.19
Ma150ch	-0.19%
Ma20	24.51
Ma20ch	-5.53%
Net CF	-139,304,000
Next Earnings Date	2026-08-04
Open	23.89
Optionable	Yes
P FCF Ratio	6.86
P OCF Ratio	6.41
Position In Range	5.22
Ppne	175,690,000
Pre Close	23.64
Price Date	2026-05-08
Price EBITDA	$7.51
Ptbv Ratio	3.24
Relative Volume	0.86x
Revenue	734,864,000x
SBC By Revenue	7.69x
Share Based Comp	56,488,000
Tax By Revenue	1.09x
Tax Rate	60.98%
Tr6m	4.99%
Us State	California
Volume	513,960
Z Score	2.02

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does PCRX pay a dividend?

Capital-return profile for this ticker.

Performance

PCRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns PCRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+119.0%

Float: +92.5% of shares outstanding

Insider ownership

+2.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

PCRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

41.9

Neutral momentum band

Price vs 200-day MA

-2.2%

50/200-day relationship not available

Beta (5Y)

0.32

Less volatile than the market

Sharpe ratio

-0.14

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About PCRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current PCRX stock rating?

Pacira BioSciences, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full PCRX analysis?

The full report lives at /stocks/PCRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for PCRX?

The latest report frames PCRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the PCRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.